beclometasone dipropionate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
prednisone and prednisolone derivatives	294	5534-09-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: rhinocort beclometasone dipropionate beclomethasone dipropionate beclomethasone dipropionate monohydrate	An anti-inflammatory, synthetic glucocorticoid. It is used topically as an anti-inflammatory agent and in aerosol form for the treatment of ASTHMA. Molecular weight: 521.05 Formula: C28H37ClO7 CLOGP: 4.26 LIPINSKI: 1 HAC: 7 HDO: 1 TPSA: 106.97 ALOGS: -5.40 ROTB: 8 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

rhinocort
beclometasone dipropionate
beclomethasone dipropionate
beclomethasone dipropionate monohydrate

An anti-inflammatory, synthetic glucocorticoid. It is used topically as an anti-inflammatory agent and in aerosol form for the treatment of ASTHMA.

Molecular weight: 521.05
Formula: C28H37ClO7
CLOGP: 4.26
LIPINSKI: 1
HAC: 7
HDO: 1
TPSA: 106.97
ALOGS: -5.40
ROTB: 8

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.40	mg	N
0.80	mg	Inhal.aerosol
0.80	mg	Inhal.powder
1.50	mg	Inhal.solution

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.05 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	0.29 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	36 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.13 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.50 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
May 12, 1976	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Asthma	366.04	12.32	304	21363	89033	50494424
Wheezing	167.03	12.32	167	21500	61880	50521577
Dyspnoea	87.04	12.32	462	21205	547146	50036311
Drug ineffective	70.10	12.32	155	21512	819178	49764279
Lip swelling	67.26	12.32	67	21600	24669	50558788
Chest discomfort	66.49	12.32	132	21535	92590	50490867
Depressed mood	65.87	12.32	77	21590	33946	50549511
Cough	61.86	12.32	235	21432	241029	50342428
Swelling face	61.53	12.32	93	21574	52502	50530955
Nightmare	60.06	12.32	52	21615	16034	50567423
Swollen tongue	55.76	12.32	65	21602	28565	50554892
Bronchospasm	55.42	12.32	48	21619	14806	50568651
Rheumatoid arthritis	53.14	12.32	11	21656	202539	50380918
Asthmatic crisis	44.51	12.32	19	21648	1609	50581848
Contraindicated product administered	43.67	12.32	6	21661	148952	50434505
Systemic lupus erythematosus	42.84	12.32	5	21662	140617	50442840
Blood electrolytes abnormal	42.79	12.32	16	21651	957	50582500
Malaise	42.50	12.32	267	21400	335265	50248192
Toxicity to various agents	42.35	12.32	19	21648	212480	50370977
Death	41.44	12.32	47	21620	325332	50258125
Treatment failure	39.29	12.32	6	21661	137631	50445826
Periorbital swelling	38.77	12.32	18	21649	1859	50581598
Transient ischaemic attack	37.72	12.32	57	21610	32153	50551304
Infusion related reaction	37.32	12.32	13	21654	169544	50413913
Separation anxiety disorder	37.12	12.32	7	21660	23	50583434
Arthropathy	36.71	12.32	11	21656	157895	50425562
Flashback	36.30	12.32	9	21658	129	50583328
Bronchial secretion retention	35.96	12.32	16	21651	1497	50581960
Middle insomnia	34.88	12.32	31	21636	9890	50573567
Sputum discoloured	34.06	12.32	35	21632	13360	50570097
Anaphylactic reaction	34.06	12.32	73	21594	53982	50529475
Throat tightness	33.56	12.32	43	21624	20804	50562653
Squamous cell carcinoma of the oral cavity	33.52	12.32	10	21657	295	50583162
Nonspecific reaction	33.48	12.32	16	21651	1763	50581694
Paraesthesia oral	33.02	12.32	33	21634	12188	50571269
Productive cough	33.01	12.32	71	21596	52623	50530834
Eosinophilic granulomatosis with polyangiitis	32.05	12.32	16	21651	1939	50581518
Aggression	31.57	12.32	42	21625	21074	50562383
Bacterial disease carrier	30.86	12.32	12	21655	799	50582658
Infective pulmonary exacerbation of cystic fibrosis	30.40	12.32	26	21641	7883	50575574
Dizziness	30.16	12.32	252	21415	346117	50237340
Obstructive airways disorder	29.58	12.32	35	21632	15617	50567840
Anxiety	29.45	12.32	152	21515	177454	50406003
Miller Fisher syndrome	29.08	12.32	7	21660	88	50583369
Drug monitoring procedure not performed	29.08	12.32	10	21657	469	50582988
Pharyngeal swelling	28.47	12.32	20	21647	4546	50578911
Abdominal rigidity	28.09	12.32	14	21653	1690	50581767
Off label use	27.12	12.32	108	21559	474318	50109139
Limb injury	26.84	12.32	38	21629	20212	50563245
Rash macular	26.78	12.32	37	21630	19240	50564217
Arterial spasm	26.27	12.32	6	21661	59	50583398
Differential white blood cell count abnormal	25.39	12.32	10	21657	689	50582768
Dermatitis allergic	24.96	12.32	29	21638	12691	50570766
Dysmetropsia	24.96	12.32	6	21661	75	50583382
Sinusitis	24.90	12.32	141	21526	170417	50413040
Forced expiratory volume decreased	24.54	12.32	18	21649	4376	50579081
Gastric mucosa erythema	24.38	12.32	7	21660	180	50583277
Eye movement disorder	24.00	12.32	18	21649	4527	50578930
Sleep disorder due to a general medical condition	23.88	12.32	22	21645	7349	50576108
Abdominal discomfort	23.86	12.32	39	21628	231602	50351855
Glossodynia	23.53	12.32	10	21657	115559	50467898
Breast conserving surgery	23.46	12.32	10	21657	844	50582613
Palpitations	23.27	12.32	91	21576	94415	50489042
Pregnancy with implant contraceptive	23.08	12.32	13	21654	2010	50581447
Angioplasty	22.75	12.32	11	21656	1244	50582213
Oropharyngeal pain	22.58	12.32	79	21588	77722	50505735
Idiopathic orbital inflammation	22.18	12.32	6	21661	123	50583334
Secretion discharge	20.35	12.32	23	21644	9768	50573689
Superinfection	20.23	12.32	12	21655	2044	50581413
Urticaria	20.16	12.32	109	21558	129452	50454005
Bronchitis	20	12.32	93	21574	104066	50479391
Gingival swelling	19.97	12.32	15	21652	3780	50579677
Essential tremor	19.83	12.32	9	21658	882	50582575
Sinus operation	19.63	12.32	11	21656	1685	50581772
Facial pain	19.56	12.32	20	21647	7589	50575868
Choking	19.46	12.32	21	21646	8477	50574980
Hiccups	19.37	12.32	11	21656	1728	50581729
Hyponatraemia	19.32	12.32	87	21580	96052	50487405
Anger	19.23	12.32	24	21643	11309	50572148
Therapeutic product effect decreased	19.15	12.32	18	21649	136032	50447425
Gastroenteritis aeromonas	19.11	12.32	4	21663	25	50583432
Peripheral vascular disorder	19.05	12.32	17	21650	5450	50578007
Myalgia	18.95	12.32	104	21563	124215	50459242
Rhinovirus infection	18.67	12.32	14	21653	3520	50579937
Hepatic enzyme increased	18.39	12.32	19	21648	137361	50446096
Tongue pruritus	18.37	12.32	7	21660	441	50583016
Migraine	18.14	12.32	72	21595	75208	50508249
Drug intolerance	18.12	12.32	42	21625	219062	50364395
Nail infection	18.04	12.32	11	21656	1970	50581487
Nasal discomfort	17.43	12.32	14	21653	3890	50579567
Status asthmaticus	17.24	12.32	8	21659	825	50582632
Brain contusion	17.08	12.32	7	21660	535	50582922
Discomfort	16.89	12.32	13	21654	108367	50475090
Alopecia	16.48	12.32	52	21615	244995	50338462
Drug abuse	16.20	12.32	3	21664	59843	50523614
Respiration abnormal	16.09	12.32	15	21652	5087	50578370
Musculoskeletal stiffness	15.84	12.32	19	21648	128462	50454995
Antipsychotic drug level increased	15.72	12.32	12	21655	3097	50580360
Derealisation	15.51	12.32	8	21659	1038	50582419
Pain	15.47	12.32	166	21501	578737	50004720
Oral mucosa erosion	15.45	12.32	8	21659	1047	50582410
Urinary incontinence	15.41	12.32	36	21631	28172	50555285
Malignant neoplasm progression	15.36	12.32	5	21662	68119	50515338
Skin exfoliation	15.30	12.32	40	21627	33572	50549885
Bladder irritation	15.18	12.32	5	21662	205	50583252
Cytomegalovirus enteritis	14.78	12.32	5	21662	223	50583234
Tendonitis	14.72	12.32	26	21641	16679	50566778
Pneumonia streptococcal	14.71	12.32	9	21658	1622	50581835
Reperfusion arrhythmia	14.55	12.32	5	21662	234	50583223
Necrosis ischaemic	14.47	12.32	7	21660	792	50582665
Lacrimation increased	14.40	12.32	26	21641	16966	50566491
Product dosage form issue	13.80	12.32	3	21664	23	50583434
Skin fragility	13.80	12.32	6	21661	531	50582926
Anaemia	13.43	12.32	59	21608	252397	50331060
Headache	13.40	12.32	297	21370	506238	50077219
Platelet count decreased	13.40	12.32	14	21653	100712	50482745
Poor peripheral circulation	13.26	12.32	11	21656	3197	50580260
Mobility decreased	13.22	12.32	9	21658	79939	50503518
Hyperkinesia	13.06	12.32	8	21659	1444	50582013
Oral mucosal blistering	13.01	12.32	13	21654	4799	50578658
Product administered to patient of inappropriate age	12.97	12.32	10	21657	2620	50580837
Nasal discharge discolouration	12.75	12.32	8	21659	1506	50581951
Joint swelling	12.64	12.32	58	21609	245228	50338229
Lethargy	12.49	12.32	48	21619	49384	50534073
Stomatitis	12.48	12.32	15	21652	101329	50482128
Acute myocardial infarction	12.48	12.32	34	21633	29239	50554218
Angioedema	12.47	12.32	40	21627	37636	50545821
Helicobacter infection	12.41	12.32	3	21664	49699	50533758
Viral haemorrhagic cystitis	12.34	12.32	6	21661	687	50582770

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Asthma	298.36	12.95	185	12733	33664	29527945
Wheezing	135.83	12.95	114	12804	33126	29528483
Dyspnoea	78.28	12.95	315	12603	326417	29235192
Sleep terror	75.41	12.95	23	12895	718	29560891
Lip swelling	62.18	12.95	48	12870	12362	29549247
Ballismus	60.41	12.95	12	12906	54	29561555
Anger	58.70	12.95	44	12874	10846	29550763
Nightmare	56.85	12.95	44	12874	11373	29550236
Swollen tongue	51.97	12.95	43	12875	12223	29549386
Blood immunoglobulin E increased	44.02	12.95	20	12898	1927	29559682
Lower respiratory tract infection	43.93	12.95	56	12862	26446	29535163
Pharyngeal oedema	42.12	12.95	28	12890	5706	29555903
Infective pulmonary exacerbation of cystic fibrosis	39.99	12.95	28	12890	6208	29555401
Malaise	37.25	12.95	153	12765	159449	29402160
Attention-seeking behaviour	33.85	12.95	7	12911	40	29561569
Nasal disorder	33.12	12.95	15	12903	1434	29560175
Abnormal behaviour	32.38	12.95	45	12873	23082	29538527
Acquired macroglossia	32.11	12.95	6	12912	18	29561591
Anosmia	31.47	12.95	16	12902	1975	29559634
Chest discomfort	29.18	12.95	63	12855	45920	29515689
Neuropsychiatric symptoms	28.58	12.95	10	12908	484	29561125
Chorea	28.42	12.95	12	12906	969	29560640
Cough	26.83	12.95	118	12800	126609	29435000
Dyspnoea at rest	26.81	12.95	17	12901	3197	29558412
Nasal discomfort	25.99	12.95	12	12906	1200	29560409
Sputum discoloured	25.71	12.95	22	12896	6541	29555068
Central obesity	25.05	12.95	9	12909	471	29561138
Daydreaming	25.01	12.95	9	12909	473	29561136
Neonatal hyponatraemia	24.99	12.95	6	12912	73	29561536
Toxicity to various agents	24.34	12.95	24	12894	173637	29387972
Crepitations	24.14	12.95	15	12903	2724	29558885
Death	23.64	12.95	74	12844	342010	29219599
Crying	23.16	12.95	19	12899	5332	29556277
Gastric ulcer perforation	22.98	12.95	10	12908	870	29560739
Paraesthesia oral	22.96	12.95	16	12902	3521	29558088
Gastrointestinal tract irritation	22.75	12.95	7	12911	225	29561384
Micturition urgency	21.62	12.95	18	12900	5155	29556454
Productive cough	21.18	12.95	44	12874	31215	29530394
Neuropsychiatric syndrome	20.89	12.95	5	12913	60	29561549
Spleen congestion	20.78	12.95	7	12911	302	29561307
Cervicogenic headache	20.72	12.95	4	12914	15	29561594
Chronic obstructive pulmonary disease	20.36	12.95	51	12867	40904	29520705
Completed suicide	20.36	12.95	7	12911	90239	29471370
Palpitations	19.91	12.95	44	12874	32560	29529049
Bronchomalacia	19.11	12.95	5	12913	88	29561521
Eye swelling	18.80	12.95	21	12897	8636	29552973
Mesothelioma	18.79	12.95	7	12911	406	29561203
Depressed mood	18.67	12.95	29	12889	16419	29545190
Benign prostatic hyperplasia	18.23	12.95	24	12894	11686	29549923
Mood swings	18.22	12.95	19	12899	7232	29554377
Locked-in syndrome	18.13	12.95	6	12912	245	29561364
Suicidal ideation	18.07	12.95	44	12874	34672	29526937
Malignant neoplasm progression	17.97	12.95	5	12913	73854	29487755
Nasal septum perforation	17.80	12.95	5	12913	116	29561493
Platelet count decreased	17.71	12.95	12	12906	104660	29456949
Self-injurious ideation	17.60	12.95	10	12908	1541	29560068
Convulsive threshold lowered	17.45	12.95	7	12911	496	29561113
Angioedema	17.20	12.95	41	12877	31874	29529735
Antibody test abnormal	17.05	12.95	5	12913	136	29561473
Multifocal motor neuropathy	17.03	12.95	4	12914	44	29561565
Rash papular	16.71	12.95	19	12899	7962	29553647
Hepatic cancer	16.37	12.95	17	12901	6439	29555170
Aortic dissection	15.98	12.95	11	12907	2373	29559236
Urticaria	15.66	12.95	56	12862	54604	29507005
Renal aplasia	15.56	12.95	7	12911	659	29560950
Anaphylactic reaction	15.49	12.95	36	12882	27537	29534072
Tryptase increased	15.32	12.95	5	12913	195	29561414
Thrombocytopenia	15.28	12.95	22	12896	134801	29426808
Sinusitis	15.25	12.95	41	12877	34309	29527300
Ageusia	14.98	12.95	19	12899	8919	29552690
Product administered to patient of inappropriate age	14.91	12.95	11	12907	2644	29558965
Headache	14.83	12.95	128	12790	173879	29387730
Renal failure	14.82	12.95	18	12900	118581	29443028
Eosinophilia	14.78	12.95	31	12887	22130	29539479
Obstructive airways disorder	14.77	12.95	21	12897	10995	29550614
Weaning failure	14.75	12.95	5	12913	220	29561389
Ejaculation failure	14.61	12.95	7	12911	760	29560849
Nasal inflammation	14.53	12.95	5	12913	230	29561379
Neonatal seizure	14.29	12.95	6	12912	478	29561131
Ocular discomfort	14.25	12.95	9	12909	1680	29559929
Violence-related symptom	14.02	12.95	6	12912	501	29561108
Infarction	13.51	12.95	10	12908	2416	29559193
Apnoeic attack	13.15	12.95	5	12913	307	29561302

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Asthma	516.24	11.63	395	29555	94830	64373952
Wheezing	263.01	11.63	250	29700	80329	64388453
Dyspnoea	134.03	11.63	672	29278	718002	63750780
Lip swelling	127.51	11.63	111	29839	31796	64436986
Nightmare	124.38	11.63	92	29858	20901	64447881
Swollen tongue	105.54	11.63	104	29846	34850	64433932
Depressed mood	88.34	11.63	102	29848	40910	64427872
Sleep terror	82.31	11.63	28	29922	1169	64467613
Completed suicide	81.24	11.63	6	29944	224408	64244374
Chest discomfort	77.08	11.63	168	29782	115938	64352844
Swelling face	74.40	11.63	113	29837	59053	64409729
Anger	73.67	11.63	60	29890	15681	64453101
Malaise	73.06	11.63	370	29580	395877	64072905
Toxicity to various agents	68.64	11.63	42	29908	363471	64105311
Drug ineffective	66.33	11.63	187	29763	840060	63628722
Infective pulmonary exacerbation of cystic fibrosis	63.88	11.63	49	29901	11747	64457035
Death	59.02	11.63	83	29867	482622	63986160
Sputum discoloured	55.51	11.63	54	29896	17802	64450980
Cough	53.41	11.63	279	29671	301869	64166913
Paraesthesia oral	51.07	11.63	45	29905	13086	64455696
Bronchospasm	48.49	11.63	55	29895	21627	64447155
Drug abuse	46.59	11.63	4	29946	132370	64336412
Ballismus	46.31	11.63	12	29938	190	64468592
Dizziness	45.87	11.63	349	29601	429814	64038968
Pharyngeal oedema	44.63	11.63	45	29905	15486	64453296
Rheumatoid arthritis	44.06	11.63	11	29939	164283	64304499
Separation anxiety disorder	41.84	11.63	8	29942	26	64468756
Asthmatic crisis	41.64	11.63	19	29931	1737	64467045
Productive cough	40.89	11.63	99	29851	73104	64395678
Periorbital swelling	40.44	11.63	19	29931	1857	64466925
Palpitations	40.03	11.63	123	29827	104365	64364417
Infusion related reaction	38.68	11.63	14	29936	164453	64304329
Treatment failure	37.36	11.63	5	29945	116811	64351971
Abnormal behaviour	36.42	11.63	60	29890	33562	64435220
Obstructive airways disorder	36.05	11.63	49	29901	23136	64445646
Eosinophilic granulomatosis with polyangiitis	35.43	11.63	20	29930	2862	64465920
Transient ischaemic attack	35.25	11.63	69	29881	44113	64424669
Off label use	35.08	11.63	163	29787	632643	63836139
Anxiety	34.30	11.63	185	29765	202464	64266318
Aggression	34.24	11.63	70	29880	46162	64422620
Malignant neoplasm progression	33.44	11.63	6	29944	112865	64355917
Crepitations	32.54	11.63	28	29922	7887	64460895
Rash macular	32.28	11.63	47	29903	23638	64445144
Synovitis	32.27	11.63	4	29946	99086	64369696
Blood electrolytes abnormal	32.15	11.63	16	29934	1775	64467007
Attention-seeking behaviour	32.06	11.63	8	29942	108	64468674
Contraindicated product administered	31.37	11.63	6	29944	107823	64360959
Anaphylactic reaction	31.27	11.63	86	29864	68578	64400204
Middle insomnia	31.09	11.63	34	29916	12843	64455939
Bacterial disease carrier	30.80	11.63	13	29937	986	64467796
Angioedema	30.74	11.63	80	29870	61741	64407041
Blood immunoglobulin E increased	30.12	11.63	20	29930	3824	64464958
Dermatitis allergic	29.90	11.63	36	29914	15073	64453709
Pharyngeal swelling	29.89	11.63	23	29927	5536	64463246
Myalgia	29.73	11.63	149	29801	158468	64310314
Forced expiratory volume decreased	29.68	11.63	25	29925	6842	64461940
Urticaria	29.48	11.63	141	29809	147176	64321606
Arthropathy	28.95	11.63	10	29940	120957	64347825
Throat tightness	28.76	11.63	44	29906	23116	64445666
Squamous cell carcinoma of the oral cavity	28.45	11.63	10	29940	461	64468321
Nonspecific reaction	27.64	11.63	15	29935	1988	64466794
Gingival swelling	27.39	11.63	19	29931	3901	64464881
Essential tremor	27.33	11.63	13	29937	1306	64467476
Oropharyngeal pain	27.22	11.63	97	29853	88770	64380012
Antipsychotic drug level increased	27.15	11.63	21	29929	5094	64463688
Bronchial secretion retention	26.98	11.63	16	29934	2511	64466271
Thrombocytopenia	26.77	11.63	39	29911	223762	64245020
Pregnancy with implant contraceptive	26.04	11.63	13	29937	1451	64467331
Breast conserving surgery	26.01	11.63	10	29940	595	64468187
Choking	25.74	11.63	28	29922	10510	64458272
Systemic lupus erythematosus	25.60	11.63	3	29947	77609	64391173
Miller Fisher syndrome	24.72	11.63	7	29943	157	64468625
Platelet count decreased	24.52	11.63	25	29925	167686	64301096
Micturition urgency	24.40	11.63	27	29923	10332	64458450
Sinus operation	24.25	11.63	13	29937	1682	64467100
Limb injury	24.19	11.63	41	29909	23464	64445318
Dysmetropsia	23.78	11.63	6	29944	85	64468697
Crying	23.32	11.63	37	29913	20053	64448729
Anosmia	23.15	11.63	18	29932	4399	64464383
Drug monitoring procedure not performed	23.04	11.63	10	29940	812	64467970
Hallucination	22.76	11.63	80	29870	72708	64396074
Bleeding time prolonged	22.49	11.63	11	29939	1175	64467607
Hepatic enzyme increased	21.84	11.63	17	29933	129926	64338856
Pain	21.82	11.63	159	29791	553352	63915430
Angioplasty	21.55	11.63	12	29938	1673	64467109
Neuropsychiatric symptoms	21.49	11.63	10	29940	956	64467826
Migraine	21.45	11.63	71	29879	62606	64406176
Abdominal rigidity	21.39	11.63	14	29936	2613	64466169
Flashback	21.36	11.63	7	29943	260	64468522
Anaemia	21.24	11.63	97	29853	378583	64090199
Idiopathic orbital inflammation	20.89	11.63	6	29944	142	64468640
Arterial spasm	20.35	11.63	6	29944	156	64468626
Nasal disorder	20.20	11.63	14	29936	2870	64465912
Mood swings	20.04	11.63	32	29918	17436	64451346
Daydreaming	19.95	11.63	9	29941	801	64467981
Irritability	19.77	11.63	49	29901	36697	64432085
Headache	19.65	11.63	350	29600	529117	63939665
Chorea	19.64	11.63	12	29938	1988	64466794
Febrile neutropenia	19.36	11.63	36	29914	187621	64281161
Ejaculation failure	19.29	11.63	7	29943	354	64468428
Suicidal ideation	19.00	11.63	71	29879	66471	64402311
Cervicogenic headache	18.79	11.63	4	29946	25	64468757
Gastroenteritis aeromonas	18.79	11.63	4	29946	25	64468757
Acquired macroglossia	18.73	11.63	6	29944	207	64468575
Disease progression	18.65	11.63	23	29927	141657	64327125
Sleep disorder due to a general medical condition	18.60	11.63	21	29929	8213	64460569
Nasal discharge discolouration	18.45	11.63	11	29939	1743	64467039
Product administered to patient of inappropriate age	18.36	11.63	16	29934	4585	64464197
Liver function test abnormal	18.32	11.63	65	29885	59336	64409446
Skin exfoliation	18.27	11.63	54	29896	44831	64423951
Disturbance in attention	18.25	11.63	51	29899	41023	64427759
Secretion discharge	18.16	11.63	25	29925	11939	64456843
Differential white blood cell count abnormal	18.13	11.63	11	29939	1799	64466983
Upper gastrointestinal haemorrhage	17.94	11.63	46	29904	35174	64433608
Nail infection	17.93	11.63	11	29939	1836	64466946
Spleen congestion	17.91	11.63	7	29943	435	64468347
Renal failure	17.75	11.63	36	29914	181652	64287130
Eye movement disorder	17.63	11.63	19	29931	7060	64461722
Central obesity	17.62	11.63	10	29940	1445	64467337
Neuropsychiatric syndrome	17.38	11.63	5	29945	119	64468663
Psychomotor hyperactivity	17.31	11.63	27	29923	14424	64454358
Tongue pruritus	17.24	11.63	7	29943	481	64468301
Benign prostatic hyperplasia	16.78	11.63	21	29929	9144	64459638
Multifocal motor neuropathy	16.78	11.63	4	29946	44	64468738
Poor peripheral circulation	16.68	11.63	13	29937	3187	64465595
Tendonitis	16.57	11.63	32	29918	20250	64448532
Gastrointestinal tract irritation	16.48	11.63	7	29943	539	64468243
Infection	16.11	11.63	39	29911	184841	64283941
Encephalopathy	15.64	11.63	4	29946	58815	64409967
Hyponatraemia	15.54	11.63	120	29830	148219	64320563
Peripheral vascular disorder	15.53	11.63	18	29932	7243	64461539
Status asthmaticus	15.48	11.63	8	29942	960	64467822
Muscle spasms	15.29	11.63	115	29835	140908	64327874
Pericarditis	15.25	11.63	5	29945	62511	64406271
Urinary incontinence	15.20	11.63	44	29906	36107	64432675
Lactic acidosis	14.82	11.63	5	29945	61405	64407377
Bronchomalacia	14.51	11.63	5	29945	217	64468565
Eye swelling	14.49	11.63	32	29918	22249	64446533
Overdose	14.43	11.63	33	29917	159533	64309249
Rhinovirus infection	14.42	11.63	16	29934	6140	64462642
Lower respiratory tract infection	14.40	11.63	84	29866	94530	64374252
Bladder irritation	14.32	11.63	5	29945	226	64468556
Facial pain	14.31	11.63	18	29932	7877	64460905
Hypotension	14.24	11.63	111	29839	380863	64087919
Ageusia	14.09	11.63	24	29926	13789	64454993
Pulmonary congestion	14.09	11.63	33	29917	23847	64444935
Respiration abnormal	14.08	11.63	16	29934	6299	64462483
Dyspnoea at rest	14.06	11.63	16	29934	6313	64462469
Cardio-respiratory arrest	14.00	11.63	15	29935	98378	64370404
Skin fragility	13.94	11.63	7	29943	791	64467991
Abnormal weight gain	13.78	11.63	10	29940	2203	64466579
Nasal septum ulceration	13.56	11.63	3	29947	23	64468759
Platelet count increased	13.48	11.63	28	29922	18668	64450114
Hypovolaemia	13.35	11.63	25	29925	15461	64453321
Gastric ulcer perforation	13.26	11.63	9	29941	1784	64466998
Reperfusion arrhythmia	13.17	11.63	5	29945	287	64468495
Convulsive threshold lowered	13.16	11.63	7	29943	892	64467890
Pneumonia streptococcal	13.14	11.63	10	29940	2368	64466414
Syncope	13.05	11.63	121	29829	157514	64311268
Blood pressure fluctuation	12.91	11.63	4	29946	51867	64416915
Beta haemolytic streptococcal infection	12.81	11.63	9	29941	1885	64466897
Mood altered	12.79	11.63	25	29925	15954	64452828
Intentional product misuse	12.73	11.63	9	29941	72286	64396496
Orthostatic hypotension	12.62	11.63	49	29901	46689	64422093
Necrosis ischaemic	12.57	11.63	7	29943	976	64467806
Superinfection	12.54	11.63	12	29938	3874	64464908
Self-injurious ideation	12.52	11.63	11	29939	3186	64465596
Drug intolerance	12.51	11.63	45	29905	187947	64280835
White blood cell count decreased	12.45	11.63	35	29915	157802	64310980
Contusion	12.38	11.63	93	29857	113872	64354910
Musculoskeletal stiffness	12.38	11.63	24	29926	123182	64345600
Locked-in syndrome	12.36	11.63	6	29944	630	64468152
Blood creatinine increased	12.34	11.63	28	29922	135754	64333028
Suicide attempt	12.30	11.63	9	29941	70998	64397784
Vaginal discharge	12.26	11.63	12	29938	3985	64464797
Derealisation	12.25	11.63	8	29942	1487	64467295
Graft versus host disease in gastrointestinal tract	12.15	11.63	14	29936	5598	64463184
Eosinophilia	12.03	11.63	42	29908	38034	64430748
Hepatic cancer	11.97	11.63	16	29934	7432	64461350
Gastric mucosa erythema	11.96	11.63	5	29945	370	64468412
Nasal pruritus	11.90	11.63	5	29945	375	64468407
Pancytopenia	11.89	11.63	31	29919	143278	64325504
Violence-related symptom	11.86	11.63	6	29944	689	64468093
Nasal congestion	11.84	11.63	57	29893	59601	64409181
Inflammatory myofibroblastic tumour	11.80	11.63	4	29946	165	64468617
Rhonchi	11.76	11.63	11	29939	3452	64465330
Polyp	11.76	11.63	15	29935	6658	64462124

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A07EA07	ALIMENTARY TRACT AND METABOLISM ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS INTESTINAL ANTIINFLAMMATORY AGENTS Corticosteroids acting locally
ATC	D07AC15	DERMATOLOGICALS CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS CORTICOSTEROIDS, PLAIN Corticosteroids, potent (group III)
ATC	D07CC04	DERMATOLOGICALS CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS Corticosteroids, potent, combinations with antibiotics
ATC	R01AD01	RESPIRATORY SYSTEM NASAL PREPARATIONS DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE Corticosteroids
ATC	R03AK08	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
ATC	R03AK13	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
ATC	R03AL09	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
ATC	R03BA01	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS Glucocorticoids
FDA MoA	N0000175450	Corticosteroid Hormone Receptor Agonists
FDA EPC	N0000175576	Corticosteroid
CHEBI has role	CHEBI:35472	anti-inflammatory drugs
CHEBI has role	CHEBI:49167	anti-asthmatic drugs
CHEBI has role	CHEBI:38070	antiarrhythmic agent
CHEBI has role	CHEBI:50266	Prodrugs
MeSH PA	D018927	Anti-Asthmatic Agents
MeSH PA	D000893	Anti-Inflammatory Agents
MeSH PA	D005938	Glucocorticoids
MeSH PA	D006728	Hormones
MeSH PA	D019141	Respiratory System Agents
MeSH PA	D001993	Bronchodilator Agents
MeSH PA	D018373	Peripheral Nervous System Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Vasomotor rhinitis	indication	8229003	DOID:4730
Nasal polyp	indication	52756005
Allergic rhinitis	indication	61582004
Rhinitis	indication	70076002	DOID:4483
Asthma	indication	195967001	DOID:2841
Asthma management	indication	406162001
Severe chronic obstructive pulmonary disease	off-label use	313299006
Mycosis	contraindication	3218000	DOID:1564
Ocular hypertension	contraindication	4210003	DOID:9282
Inactive tuberculosis	contraindication	11999007
Epistaxis	contraindication	12441001
Measles	contraindication	14189004	DOID:8622
Disease caused by parasite	contraindication	17322007
Glaucoma	contraindication	23986001	DOID:1686
Acute tuberculosis	contraindication	25629007
Perforation of nasal septum	contraindication	80142000
Bacterial infectious disease	contraindication	87628006
Mycobacteriosis	contraindication	88415009
Operation on nose	contraindication	88733004
Bilateral cataracts	contraindication	95722004
Ophthalmic herpes simplex	contraindication	186542001
Disease of liver	contraindication	235856003	DOID:409
Varicella-zoster virus infection	contraindication	309465005
Adrenal cortical hypofunction	contraindication	386584007	DOID:10493
Exposure to varicella	contraindication	444453009
Nasal Trauma	contraindication
Nasal Candidiasis	contraindication
Nasal Septal Ulcers	contraindication
Uncontrolled Bacterial Infections	contraindication
Untreated Fungal Infection	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	12.01	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Glucocorticoid receptor	Nuclear hormone receptor	P04150	GCR_HUMAN	AGONIST	Ki	8.43	DRUG MATRIX	CHEMBL
Interleukin-5	Cytokine	P05113	IL5_HUMAN		IC50	4.57	CHEMBL
Mineralocorticoid receptor	Nuclear hormone receptor	P08235	MCR_HUMAN		EC50	8.32	CHEMBL
Matrix metalloproteinase-9	Enzyme	P14780	MMP9_HUMAN		IC50	5.70	CHEMBL
Probable G-protein coupled receptor 97	GPCR	Q86Y34	AGRG3_HUMAN	AGONIST	EC50	8.50	IUPHAR
Progesterone receptor	Nuclear hormone receptor	P06401	PRGR_HUMAN		IC50	7.55	CHEMBL
Androgen receptor	Transcription factor		ANDR_RAT		Ki	5.96	CHEMBL
Progesterone receptor	Transcription factor		Q690N0_BOVIN		Ki	7.57	CHEMBL
Glucocorticoid receptor	Transcription factor		GCR_RAT		IC50	8.54	CHEMBL
Interleukin-5	Unclassified		IL5_MOUSE		IC50	4.58	CHEMBL
Interleukin-5 receptor subunit alpha	Unclassified		IL5RA_MOUSE		IC50	4.58	CHEMBL

External reference:

ID	Source
D00689	KEGG_DRUG
77011-63-3	SECONDARY_CAS_RN
1347	RXNORM
C0004906	UMLSCUI
CHEBI:3002	CHEBI
CHEBI:3001	CHEBI
CHEMBL1200500	ChEMBL_ID
CHEMBL1370	ChEMBL_ID
DB00394	DRUGBANK_ID
5894	IUPHAR_LIGAND_ID
7059	IUPHAR_LIGAND_ID
4419-39-0	SECONDARY_CAS_RN
21700	PUBCHEM_CID
20469	PUBCHEM_CID
1167	MMSL
4249	MMSL
71834	MMSL
8263	MMSL
d00760	MMSL
002179	NDDF
004947	NDDF
4018793	VANDF
4019625	VANDF
D019819	MESH_DESCRIPTOR_UI
D001507	MESH_DESCRIPTOR_UI
C0004905	UMLSCUI
2307	INN_ID
116574000	SNOMEDCT_US
116575004	SNOMEDCT_US
1389007	SNOMEDCT_US
426017007	SNOMEDCT_US
5B307S63B2	UNII
KGZ1SLC28Z	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
BECONASEAQ	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0388	SPRAY, SUSPENSION	42 ug	NASAL	NDA	20 sections
BECONASE AQ	HUMAN PRESCRIPTION DRUG LABEL	1	16590-030	SPRAY, SUSPENSION	42 ug	NASAL	NDA	13 sections
QVAR	HUMAN PRESCRIPTION DRUG LABEL	1	16590-860	AEROSOL, METERED	40 ug	RESPIRATORY (INHALATION)	NDA	26 sections
QVAR	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1342	AEROSOL, METERED	80 ug	RESPIRATORY (INHALATION)	NDA	28 sections
QVAR	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3033	AEROSOL, METERED	40 ug	RESPIRATORY (INHALATION)	NDA	28 sections
QVAR REDIHALER	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3459	AEROSOL, METERED	80 ug	RESPIRATORY (INHALATION)	NDA	16 sections
QVAR REDIHALER	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5031	AEROSOL, METERED	40 ug	RESPIRATORY (INHALATION)	NDA	17 sections
QVAR REDIHALER	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5032	AEROSOL, METERED	80 ug	RESPIRATORY (INHALATION)	NDA	17 sections
QVAR REDIHALER	HUMAN PRESCRIPTION DRUG LABEL	1	53002-2436	AEROSOL, METERED	40 ug	RESPIRATORY (INHALATION)	NDA	16 sections
QVAR REDIHALER	HUMAN PRESCRIPTION DRUG LABEL	1	53002-3477	AEROSOL, METERED	80 ug	RESPIRATORY (INHALATION)	NDA	16 sections
QVAR	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5857	AEROSOL, METERED	40 ug	RESPIRATORY (INHALATION)	NDA	14 sections
QVAR	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5858	AEROSOL, METERED	80 ug	RESPIRATORY (INHALATION)	NDA	14 sections
QVAR REDIHALER	HUMAN PRESCRIPTION DRUG LABEL	1	59310-302	AEROSOL, METERED	40 ug	RESPIRATORY (INHALATION)	NDA	17 sections
QVAR REDIHALER	HUMAN PRESCRIPTION DRUG LABEL	1	59310-302	AEROSOL, METERED	40 ug	RESPIRATORY (INHALATION)	NDA	17 sections
QVAR REDIHALER	HUMAN PRESCRIPTION DRUG LABEL	1	59310-304	AEROSOL, METERED	80 ug	RESPIRATORY (INHALATION)	NDA	17 sections
QVAR REDIHALER	HUMAN PRESCRIPTION DRUG LABEL	1	59310-304	AEROSOL, METERED	80 ug	RESPIRATORY (INHALATION)	NDA	17 sections
QNASL	HUMAN PRESCRIPTION DRUG LABEL	1	59310-406	AEROSOL, METERED	40 ug	NASAL	NDA	27 sections
QNASL	HUMAN PRESCRIPTION DRUG LABEL	1	59310-406	AEROSOL, METERED	40 ug	NASAL	NDA	27 sections
QNASL	HUMAN PRESCRIPTION DRUG LABEL	1	59310-410	AEROSOL, METERED	80 ug	NASAL	NDA	27 sections
QNASL	HUMAN PRESCRIPTION DRUG LABEL	1	59310-410	AEROSOL, METERED	80 ug	NASAL	NDA	27 sections